X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the collaboration, Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases.
Lead Product(s): GBA1 Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $1,675.0 million Upfront Cash: $175.0 million
Deal Type: Collaboration April 16, 2024
Details:
Through collabraotion, Neurocrine will to focus on the development and commercialization of VY-FXN01, which helps to restore FXN protein levels. It is being evaluated in the treatment of Friedreich’s ataxia.
Lead Product(s): VY-FXN01
Therapeutic Area: Genetic Disease Product Name: VY-FXN01
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $1,865.0 million Upfront Cash: $165.0 million
Deal Type: Collaboration February 26, 2024
Details:
VY-TAU01 is a BBB-penetrant AAV containing primary artificial microRNA targeting tau silencing gene therapy. It is being evaluated for the treatment of Alzheimer’s Disease.
Lead Product(s): VY-TAU01
Therapeutic Area: Neurology Product Name: VY-TAU01
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The Company intends to use the net proceeds to advance its anti-tau antibody program, VY-TAU01, for the treatment of Alzheimer’s disease (AD) and its SOD1 silencing gene therapy program for the treatment of amyotrophic lateral sclerosis (ALS) into clinical development.
Lead Product(s): VY-TAU01
Therapeutic Area: Neurology Product Name: VY-TAU01
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 04, 2024
Details:
Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER™ capsids and other intellectual property, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for Huntington’s disease and spinal muscular atrophy.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,300.0 million Upfront Cash: $100.0 million
Deal Type: Collaboration January 02, 2024
Details:
SOD1-ALS is a cell and gene therapy administered via intravenous injection, targeting superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis.
Lead Product(s): SOD1-ALS
Therapeutic Area: Neurology Product Name: SOD1-ALS
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
Under the terms of the agreement, Sangamo has received a non-exclusive license to combine a Voyager TRACER capsid with Sangamo’s ZF-TRs (zinc finger transcriptional regulator) designed to treat prion disease.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sangamo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 29, 2023
Details:
Under the agreement, Novartis licenses novel capsids generated from Voyager’s TRACER™ capsid discovery platform for use in gene therapy programs against two undisclosed neurologic disease targets.
Lead Product(s): AAV-based Capsid
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,754.0 million Upfront Cash: $54.0 million
Deal Type: Licensing Agreement March 06, 2023
Details:
Under the collaboration, Neurocrine will receive worldwide rights to Voyager’s GBA1 gene therapy program for Parkinson’s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare CNS targets.
Lead Product(s): GBA1-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $1,675.0 million Upfront Cash: $175.0 million
Deal Type: Collaboration January 09, 2023
Details:
Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in the creation of novel capsids with the potential to power programs in Voyager’s pipeline and supporting Voyager alliances with leading biopharma partners.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: Touchlight
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
